Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Align Technology, Inc. stock logo
ALGN
Align Technology
$310.50
-1.0%
$313.38
$176.34
$413.20
$23.61B1.65571,944 shs1.65 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$138.01
+0.1%
$130.98
$74.75
$142.00
$54.60B1.22.33 million shs4.20 million shs
Eisai Co., Ltd. stock logo
ESALY
Eisai
$61.51
-2.1%
$61.51
$36.88
$73.90
$17.64B0.3160,916 shs331,800 shs
Olympus Co. stock logo
OCPNY
Olympus
$18.00
-1.4%
$18.00
$16.80
$74.99
$23.15B0.7860,265 shs400 shs
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$23.88
-2.8%
$26.06
$21.52
$33.08
$10.74B0.731.02 million shs1.17 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Align Technology, Inc. stock logo
ALGN
Align Technology
-1.05%+3.04%-2.95%+17.49%-12.42%
DexCom, Inc. stock logo
DXCM
DexCom
+0.10%+2.76%-1.37%+13.16%+10.47%
Eisai Co., Ltd. stock logo
ESALY
Eisai
0.00%0.00%0.00%0.00%0.00%
Olympus Co. stock logo
OCPNY
Olympus
0.00%0.00%0.00%0.00%0.00%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
-2.81%-0.52%-8.44%-14.90%-25.54%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Align Technology, Inc. stock logo
ALGN
Align Technology
4.6708 of 5 stars
2.34.00.03.83.62.53.1
DexCom, Inc. stock logo
DXCM
DexCom
4.4826 of 5 stars
1.55.00.04.72.62.53.1
Eisai Co., Ltd. stock logo
ESALY
Eisai
N/AN/AN/AN/AN/AN/AN/AN/A
Olympus Co. stock logo
OCPNY
Olympus
N/AN/AN/AN/AN/AN/AN/AN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
2.1267 of 5 stars
0.03.02.50.03.40.01.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Align Technology, Inc. stock logo
ALGN
Align Technology
2.50
Moderate Buy$341.369.94% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.93
Moderate Buy$141.402.46% Upside
Eisai Co., Ltd. stock logo
ESALY
Eisai
3.00
BuyN/AN/A
Olympus Co. stock logo
OCPNY
Olympus
N/AN/AN/AN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
2.40
HoldN/AN/A

Current Analyst Ratings

Latest OCPNY, ALGN, SNN, ESALY, and DXCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2024
Align Technology, Inc. stock logo
ALGN
Align Technology
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$344.00 ➝ $360.00
4/25/2024
Align Technology, Inc. stock logo
ALGN
Align Technology
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$355.00 ➝ $375.00
4/25/2024
Align Technology, Inc. stock logo
ALGN
Align Technology
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$333.00 ➝ $370.00
4/18/2024
Align Technology, Inc. stock logo
ALGN
Align Technology
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$350.00 ➝ $400.00
4/15/2024
Align Technology, Inc. stock logo
ALGN
Align Technology
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$280.00 ➝ $320.00
4/10/2024
DexCom, Inc. stock logo
DXCM
DexCom
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$153.00 ➝ $163.00
4/3/2024
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$148.00 ➝ $161.00
3/15/2024
Align Technology, Inc. stock logo
ALGN
Align Technology
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$340.00 ➝ $350.00
3/14/2024
Align Technology, Inc. stock logo
ALGN
Align Technology
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$335.00 ➝ $355.00
3/12/2024
DexCom, Inc. stock logo
DXCM
DexCom
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$165.00
2/26/2024
Align Technology, Inc. stock logo
ALGN
Align Technology
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Align Technology, Inc. stock logo
ALGN
Align Technology
$3.86B6.05$8.37 per share37.11$47.40 per share6.55
DexCom, Inc. stock logo
DXCM
DexCom
$3.62B15.09$2.07 per share66.63$5.35 per share25.80
Eisai Co., Ltd. stock logo
ESALY
Eisai
$6.74B2.62$2.68 per share22.94$23.94 per share2.57
Olympus Co. stock logo
OCPNY
Olympus
$7.74B2.99$1.22 per share14.76$3.50 per share5.14
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$5.55B1.88$3.13 per share7.64$11.94 per share2.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Align Technology, Inc. stock logo
ALGN
Align Technology
$445.05M$6.0751.1534.695.6211.80%14.22%8.49%7/24/2024 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.31105.3561.892.3714.95%28.31%9.74%N/A
Eisai Co., Ltd. stock logo
ESALY
Eisai
$426.79M$0.8770.7051.692.464.11%3.86%2.50%N/A
Olympus Co. stock logo
OCPNY
Olympus
$1.03B$0.8221.9520.691.0713.80%24.30%9.30%N/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$263MN/A0.0011.481.32N/AN/AN/AN/A

Latest OCPNY, ALGN, SNN, ESALY, and DXCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/25/2024Q1 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.27$0.32+$0.05$0.28$911.20 million$921.00 million
2/8/2024Q4 2023
DexCom, Inc. stock logo
DXCM
DexCom
$0.43$0.50+$0.07$0.38$1.02 billion$1.03 billion      
1/31/2024Q4 2023
Align Technology, Inc. stock logo
ALGN
Align Technology
$1.78$1.91+$0.13$2.18$928.57 million$956.73 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Align Technology, Inc. stock logo
ALGN
Align Technology
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Eisai Co., Ltd. stock logo
ESALY
Eisai
$0.881.43%N/A101.15%N/A
Olympus Co. stock logo
OCPNY
Olympus
$0.080.44%N/A9.76%N/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$0.903.77%N/AN/A1 Years

Latest OCPNY, ALGN, SNN, ESALY, and DXCM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/4/2024
Smith & Nephew plc stock logo
SNN
Smith & Nephew
semi-annual$0.46202.8%4/1/20244/2/20245/22/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Align Technology, Inc. stock logo
ALGN
Align Technology
N/A
1.18
1.04
DexCom, Inc. stock logo
DXCM
DexCom
1.18
2.84
2.48
Eisai Co., Ltd. stock logo
ESALY
Eisai
0.10
2.20
1.77
Olympus Co. stock logo
OCPNY
Olympus
0.59
1.99
1.48
Smith & Nephew plc stock logo
SNN
Smith & Nephew
0.44
1.77
0.72

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Align Technology, Inc. stock logo
ALGN
Align Technology
88.43%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Eisai Co., Ltd. stock logo
ESALY
Eisai
0.03%
Olympus Co. stock logo
OCPNY
Olympus
0.03%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
25.64%

Insider Ownership

CompanyInsider Ownership
Align Technology, Inc. stock logo
ALGN
Align Technology
0.64%
DexCom, Inc. stock logo
DXCM
DexCom
0.41%
Eisai Co., Ltd. stock logo
ESALY
Eisai
N/A
Olympus Co. stock logo
OCPNY
Olympus
N/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
1.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Align Technology, Inc. stock logo
ALGN
Align Technology
21,61075.25 million74.77 millionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600396.03 million394.40 millionOptionable
Eisai Co., Ltd. stock logo
ESALY
Eisai
11,322286.77 millionN/ANot Optionable
Olympus Co. stock logo
OCPNY
Olympus
31,5571.29 billionN/ANot Optionable
Smith & Nephew plc stock logo
SNN
Smith & Nephew
18,452437.17 million432.80 millionOptionable

OCPNY, ALGN, SNN, ESALY, and DXCM Headlines

SourceHeadline
Smith & Nephew plc (NYSE:SNN) Receives Consensus Rating of "Hold" from BrokeragesSmith & Nephew plc (NYSE:SNN) Receives Consensus Rating of "Hold" from Brokerages
americanbankingnews.com - April 23 at 2:30 AM
Smith & Nephew plc (NYSE:SNN) Given Consensus Rating of "Hold" by AnalystsSmith & Nephew plc (NYSE:SNN) Given Consensus Rating of "Hold" by Analysts
marketbeat.com - April 23 at 2:29 AM
Smith & Nephew plc (NYSE:SNN) Shares Purchased by Kornitzer Capital Management Inc. KSSmith & Nephew plc (NYSE:SNN) Shares Purchased by Kornitzer Capital Management Inc. KS
marketbeat.com - April 21 at 8:14 AM
Smith & Nephew UK Ltd: Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressings role in pressure injury preventionSmith & Nephew UK Ltd: Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing's role in pressure injury prevention
finanznachrichten.de - April 18 at 8:01 AM
Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury preventionSmith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention
markets.businessinsider.com - April 18 at 8:01 AM
Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury preventionSmith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention
finance.yahoo.com - April 18 at 8:01 AM
Raymond James & Associates Sells 511,426 Shares of Smith & Nephew plc (NYSE:SNN)Raymond James & Associates Sells 511,426 Shares of Smith & Nephew plc (NYSE:SNN)
marketbeat.com - April 18 at 4:08 AM
London & Capital Asset Management Ltd Purchases Shares of 38,622 Smith & Nephew plc (NYSE:SNN)London & Capital Asset Management Ltd Purchases Shares of 38,622 Smith & Nephew plc (NYSE:SNN)
marketbeat.com - April 15 at 11:28 AM
Smith & Nephew plc (NYSE:SNN) Sees Large Drop in Short InterestSmith & Nephew plc (NYSE:SNN) Sees Large Drop in Short Interest
marketbeat.com - April 13 at 7:42 AM
Smith+Nephew (SNN) Expands in Australia With New AllianceSmith+Nephew (SNN) Expands in Australia With New Alliance
zacks.com - April 11 at 10:16 AM
Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in AustraliaSmith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia
globenewswire.com - April 8 at 6:00 PM
Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
finance.yahoo.com - April 4 at 1:20 PM
Smith+Nephews PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
globenewswire.com - April 4 at 11:13 AM
Smith+Nephew launches wound therapy system in USSmith+Nephew launches wound therapy system in US
msn.com - April 2 at 5:15 PM
Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic woundsSmith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
globenewswire.com - April 1 at 8:00 AM
Smith & Nephew plc (NYSE:SNN) Given Consensus Rating of "Moderate Buy" by BrokeragesSmith & Nephew plc (NYSE:SNN) Given Consensus Rating of "Moderate Buy" by Brokerages
marketbeat.com - March 29 at 2:29 AM
European Equities Traded in the US as American Depositary Receipts Slightly Higher ThursdayEuropean Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday
msn.com - March 28 at 12:11 PM
Smith & Nephew CFO designate John Rogers to start next weekSmith & Nephew CFO designate John Rogers to start next week
lse.co.uk - March 28 at 7:10 AM
Smith & Nephew: John Rogers Appointed CFOSmith & Nephew: John Rogers Appointed CFO
marketwatch.com - March 28 at 7:10 AM
Smith+Nephew: John Rogers To Join Board As Executive Director And CFO On 1 AprilSmith+Nephew: John Rogers To Join Board As Executive Director And CFO On 1 April
finanznachrichten.de - March 28 at 7:10 AM
Medical supplies firm Smith & Nephew teams up with mixed martial arts promoter the UFCMedical supplies firm Smith & Nephew teams up with mixed martial arts promoter the UFC
msn.com - March 25 at 7:16 PM
Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology PartnerSmith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
globenewswire.com - March 25 at 8:00 AM
Smith & Nephew: Scepticism has been overplayed, says leading investment bankSmith & Nephew: Scepticism has been overplayed, says leading investment bank
proactiveinvestors.co.uk - March 11 at 10:25 AM
Smith & Nephew plc 2023 Q4 - Results - Earnings Call PresentationSmith & Nephew plc 2023 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 28 at 1:13 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Align Technology logo

Align Technology

NASDAQ:ALGN
Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth. The segment also provides Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment; and Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and orthodontists software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface designed to enhance dental consultations; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, pay per scan, and CAD/CAM software solutions. The company was incorporated in 1997 and is headquartered in Tempe, Arizona.
DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Eisai logo

Eisai

OTCMKTS:ESALY
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
Olympus logo

Olympus

OTCMKTS:OCPNY
Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.
Smith & Nephew logo

Smith & Nephew

NYSE:SNN
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.